Trial · NCT00511004
Effect of Albendazole Dose on Treatment of Lymphatic Filariasis
NCT00511004, Phase 2, Completed, National Institute of Allergy and Infectious Diseases (NIAID); results first posted 2015-08-31
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effect of Albendazole Dose on Treatment of Lymphatic Filariasis. Trials, record NCT00511004. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00511004
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effect of Albendazole Dose on Treatment of Lymphatic Filariasis
- NCT number
- NCT00511004
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 40 participants, actual
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Conditions
- Lymphatic Filariasis
- Interventions
- Albendazole, Diethylcarbamazine
- First posted
- 2007-08-03
- Last updated
- 2015-08-31
- Results first posted
- 2015-08-31
- Limitations and caveats
- Study never fully enrolled so sample size was smaller than hoped for.
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Microfilarial Counts at 1 Year | 1 year from time enrolled | Night time microfilarial counts at 1 year |
| Secondary | Adult Worm Burdens at 2 Years | 2 years from the time enrolled. | Doppler detected worm nests at 2 years |
| Secondary | Microfilarial Levels at 2 Years | 2 years from time enrolled | Night time microfilarial levels at 2 years |
| Secondary | Brugia Specific Immunoglobulin G4 (IgG4) Antibodies | 2 years | IgG4 antibodies directed against Brugia malayi antigen |
Source ClinicalTrials.gov
Outcomes4
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Microfilarial Counts at 1 Year | 1 year from time enrolled | MF/ML | MEDIAN | |
| SECONDARY | Adult Worm Burdens at 2 Years | 2 years from the time enrolled. | By 2 years, 4 subjects in High Dose Group lost to followup | Number of nests | MEDIAN |
| SECONDARY | Microfilarial Levels at 2 Years | 2 years from time enrolled | By 2 years, 4 subjects in High Dose Group lost to followup | MF/ML | MEDIAN |
| SECONDARY | Brugia Specific Immunoglobulin G4 (IgG4) Antibodies | 2 years | By 2 years, 4 subjects in High Dose Group lost to followup | ng/ml | MEDIAN |
Source ClinicalTrials.gov
Results by group12
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Microfilarial Counts at 1 Year | Standard Therapy Annual DEC/ALB | 0 | Full Range 0 to 20 | MF/ML | |
| Microfilarial Counts at 1 Year | High Dose Annual DEC/ALB | 0 | Full Range 0 to 12 | MF/ML | |
| Microfilarial Counts at 1 Year | High Dose Semiannual DEC/ALB | 0 | Full Range 0 to 9 | MF/ML | |
| Adult Worm Burdens at 2 Years | Standard Therapy Annual DEC/ALB | 0 | Full Range 0 to 0 | Number of nests | |
| Adult Worm Burdens at 2 Years | High Dose Annual DEC/ALB | 0 | Full Range 0 to 0 | Number of nests | |
| Adult Worm Burdens at 2 Years | High Dose Semiannual DEC/ALB | 0 | Full Range 0 to 0 | Number of nests | |
| Microfilarial Levels at 2 Years | Diethylcarbamazine/Albendazole -STD | 0 | Full Range 0 to 0 | MF/ML | |
| Microfilarial Levels at 2 Years | Diethylcarbamazine/Albendazole- HD1 | 0 | Full Range 0 to 0 | MF/ML | |
| Microfilarial Levels at 2 Years | Diethylcarbamazine/Albendazole-HD2 | 0 | Full Range 0 to 0 | MF/ML | |
| Brugia Specific Immunoglobulin G4 (IgG4) Antibodies | Standard Therapy Annual DEC/ALB | 150 | Full Range 0 to 1000 | ng/ml |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 results by groupParticipant flow9
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Standard Therapy Annual DEC/ALB | 13 | |
| Overall Study | STARTED | High Dose Annual DEC/ALB | 13 | |
| Overall Study | STARTED | High Dose Semiannual DEC/ALB | 14 | |
| Overall Study | COMPLETED | Standard Therapy Annual DEC/ALB | 13 | |
| Overall Study | COMPLETED | High Dose Annual DEC/ALB | 13 | |
| Overall Study | COMPLETED | High Dose Semiannual DEC/ALB | 10 | |
| Overall Study | NOT COMPLETED | Standard Therapy Annual DEC/ALB | 0 | |
| Overall Study | NOT COMPLETED | High Dose Annual DEC/ALB | 0 | |
| Overall Study | NOT COMPLETED | High Dose Semiannual DEC/ALB | 4 |
Source ClinicalTrials.gov
Adverse events9
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Myalgia | Musculoskeletal and connective tissue disorders | Standard Therapy Annual DEC/ALB | 9 | 13 | 9 |
| other | Myalgia | Musculoskeletal and connective tissue disorders | High Dose Annual DEC/ALB | 8 | 13 | 8 |
| other | Myalgia | Musculoskeletal and connective tissue disorders | High Dose Semiannual DEC/AC=LB | 11 | 14 | 11 |
| other | Fever | Investigations | Standard Therapy Annual DEC/ALB | 5 | 13 | 5 |
| other | Fever | Investigations | High Dose Annual DEC/ALB | 4 | 13 | 4 |
| other | Fever | Investigations | High Dose Semiannual DEC/AC=LB | 4 | 14 | 4 |
| other | Nausea/Vomiting | Gastrointestinal disorders | Standard Therapy Annual DEC/ALB | 1 | 13 | 1 |
| other | Nausea/Vomiting | Gastrointestinal disorders | High Dose Annual DEC/ALB | 1 | 13 | 1 |
| other | Nausea/Vomiting | Gastrointestinal disorders | High Dose Semiannual DEC/AC=LB | 0 | 14 | 0 |
Source ClinicalTrials.gov
Adverse event totals9
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Standard Therapy Annual DEC/ALB | ||
| Total, all-cause mortality | High Dose Annual DEC/ALB | ||
| Total, all-cause mortality | High Dose Semiannual DEC/AC=LB | ||
| Total, other adverse events | Standard Therapy Annual DEC/ALB | 9 | 13 |
| Total, other adverse events | High Dose Annual DEC/ALB | 8 | 13 |
| Total, other adverse events | High Dose Semiannual DEC/AC=LB | 11 | 14 |
| Total, serious adverse events | Standard Therapy Annual DEC/ALB | 0 | 13 |
| Total, serious adverse events | High Dose Annual DEC/ALB | 0 | 13 |
| Total, serious adverse events | High Dose Semiannual DEC/AC=LB | 0 | 14 |
Source ClinicalTrials.gov
Papers3
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00511004
GET https://conductscience.org/api/trials/v1/NCT00511004/registered